IL17A and ichthyosis: Currently, the repurposing drugs in ichthyosis are focused on the use of drugs that inhibit factors related to immune system molecules such as TNF-α (infliximab, adalimumab), IL-17A (Secukinumab, Ixekizumab), IL-4, IL-12, IL-23 (Dupilumab), and IL-36 (Paller, 2020; Trials, 2021; Joosten et al., 2022; Trials, 2023).